Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in metastatic colorectal cancer
2004-002391-42Phase 2Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Feb 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in metastatic colon cancer (mCRC) (2 arms), sponsored by Central European Cooperative Oncology Group. Primary endpoint: Progression-free survival at 9 months. Started Feb 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2004-002391-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002391-42.